Virtual Reality Education for Heart Health in Breast Cancer Survivors

This study is testing a virtual reality (VR) program called Survivors' Virtual Reality Survivorship Experience (SurviVRSE). This program aims to help women who have had breast cancer and are receiving treatments like anthracyclines or trastuzumab learn about heart health. These treatments can sometimes affect the heart, a condition called cancer therapy related cardiac dysfunction (CTRCD). The study will enroll 30 women to see how easy the VR program is to use, how well people accept it, and if it helps them learn more about heart health and make healthier choices, like being more physically active. The long-term goal is to help reduce heart problems in breast cancer survivors.

Study design
This is an interventional study with 30 participants. It is not specified if it's randomized or blinded.
What's involved
You will complete a baseline survey, engage with the virtual reality intervention during one infusion treatment, and complete all education modules and games. You will also complete follow-up assessments within 2 days and 4 weeks after the intervention.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 4 weeks after the intervention to assess changes in knowledge and behaviors.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07426913

Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab

Recruiting
NAAges 18+InterventionalSupportive care
Virginia Commonwealth University
~30 participants
Updated 2026-07-02 on ClinicalTrials.gov
What's tested:Cardiovascular Health Education and Gaming through Virtual Reality

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
CTRCD Knowledge
Measured over Baseline, within 2 days post-Intervention, and 4 weeks post-intervention
+3 more outcomes measured
Breast Cancer
Anthracycline Related Cardiotoxicity in Breast Cancer
Virtual Reality
Trastuzumab
3 sites across 1 states
Virginia3
  • Arnethea Sutton, Ph.D · PRINCIPAL_INVESTIGATOR · Virginia Commonwealth University

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years of age or older
Able to speak and read in English
Actively receiving Trastuzumab or an anthracycline-based treatment
Currently receiving immunotherapy. This includes pembrolizumab and atezolizumab.
Diagnosed with stages 0-III Breast Cancer
  • CTRCD KnowledgeBaseline, within 2 days post-Intervention, and 4 weeks post-intervention

    Change in knowledge of CTRCD and in measures of improving cardiovascular health. This investigator-developed true/false knowledge survey consists of 10 items that directly assess knowledge learned in SurviVRSE. Scoring this scale will consist of summing up the total items that were answered correctly (range = 0-10; 0 = no knowledge and 10=high knowledge).

  • UsabilityWithin 2 days post-Intervention

    Usability will be assessed using the Virtual Reality System Usability Questionnaire. This 10-item measure includes prompts such as "I think I would like to use this system frequently" and "I thought the system was easy to use." Women will respond to the items using a 5-point Likert scale (1= strongly disagree and 5= strongly agree). Scores will be totaled (with some items requiring reverse-coding).

  • AcceptabilityWithin 2 days post-Intervention

    Acceptability will be assessed using the User Experience Questionnaire, a validated 8-item 7-point Likert scale survey that measures pragmatic and hedonic qualities of SurviVRSE (e.g., obstructive/supportive, complicated/easy). The UEC developers provide an Excel spreadsheet to analyze data collected from the tool. https://www.ueq-online.org/. The range of the scales is between -3 (horribly bad) to +3 (extremely good).

  • User SatisfactionWithin 2 days post-Intervention

    SurviVRSE satisfaction and engagement will be assessed using an adapted 6-item 5-point Likert scale survey (1=strongly disagree and 5=strongly agree). Items include "I could engage SurviVRSE," I would recommend SurviVRSE to another survivor," and "I liked the music." To evaluate satisfaction, the six items will be totaled. Scores will range from 6-30 with higher scores indicating greater satisfaction.